Skip to content

Ultragenyx Pharmaceutical

US · RARE #3012 by market cap Listed 1970
16.48 -0.74 -4.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:31

Recent news

  • H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/11/7
  • Company notice
    China Rare Earth Nonferrous: Notice of China Rare Earth Nonferrous Metals Co., Ltd. on Convening the Third Extraordinary Shareholders' Meeting of 2026
    SZSI · 2026/11/13
  • Company notice
    Renet Japan Group: Selected for Tokyo's "Rare Resource Emergency Collection Project." In collaboration with the Tokyo Metropolitan Government, we will further accelerate the collection of used personal computers.
    JPX · 2026/10/22
  • Company notice
    Fuji Die: The "Susteroi STN30," which reduces rare-metal usage by 90%, has been awarded the "Technical Achievement Award" at the Japan Machine Tool Industry Association Awards.
    JPX · 2026/10/26
  • Rating change
    Lynas Rare Earths Price Target Cut 2.7% to A$17.50/Share by Jefferies
    Dow Jones · 2026/10/30
  • Rating change
    BMO Capital Initiates LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating, Announces Target Price $11.95
    Market Newswire · 2026/11/2
  • Company notice
    Fuji Die: The development of [Susteroi STN30], which reduces rare metal usage by 90%, has been awarded the "Minister of Economy, Trade and Industry Award" at the 42nd Basic Materials Industry Technology Awards.
    JPX · 2026/11/10
  • BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/11/4
  • A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $22 to $36
    Market Newswire · 2026/11/6
  • Rating change
    TD Cowen Maintains LYNAS RARE EARTHS LTD(LYSCF.US) With Hold Rating, Cuts Target Price to $9.79
    Market Newswire · 2026/11/3
  • Citi Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/11/7
  • Rating change
    Lynas Rare Earths Price Target Cut 11% to A$20.50/Share by Canaccord Genuity
    Dow Jones · 2026/10/30
  • Rating change
    Cantor Fitzgerald Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $30
    Market Newswire · 2026/11/10
  • Company notice
    Rare Element Resources Ltd. | 10-Q: Quarterly report
    SEC · 2026/11/5
  • Rating change
    Ord Minnett Downgrades LYNAS RARE EARTHS LTD(LYSCF.US) to Hold Rating, Cuts Target Price to $9.49
    Market Newswire · 2026/10/30
  • Rating change
    Canaccord Genuity Adjusts Lynas Rare Earths' Price Target to AU$20.50
    MT Newswires · 2026/10/30
  • Rating change
    Northland Securities Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/11/14
  • A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $17 to $36
    Market Newswire · 2026/11/5
  • Rating change
    Roth MKM Maintains USA Rare Earth(USAR.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/11/11
  • Rating change
    UBS Initiates LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating, Announces Target Price $14.78
    Market Newswire · 2026/10/30
  • UBS Downgrades Ultragenyx Pharmaceutical(RARE.US) to Hold Rating, Cuts Target Price to $16
    Market Newswire · 2026/10/15
  • BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/10/9
  • H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/10/15
  • Company notice
    Jiangxi Jiangtung Equipment: Sponsorship Report by CITIC Securities Co., Ltd. on the Issuance of Shares by Jiangxi Jiangtung Rare and Precious Equipment Co., Ltd. to Specific Investors
    SZSI · 2026/10/10
  • Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $36
    Market Newswire · 2026/10/21

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.

Ultragenyx Pharmaceutical discussion 0 comments

Add a comment